Budesonide nebulization in preterm neonates with evolving brochopulmonary dysplasia after 14 days of life: a case series

Authors

  • Subhodh S. Sivarama Department of Neonatology, Madurai Medical College and Government Rajaji Hospital, Tamil Nadu, India http://orcid.org/0000-0002-0695-1822
  • J. Ashokraja Department of Neonatology, Madurai Medical College and Government Rajaji Hospital, Tamil Nadu, India
  • N. Muthukumaran Department of Neonatology, Madurai Medical College and Government Rajaji Hospital, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20213324

Keywords:

Bronchopulmonary dysplasia, Oxygen, Newborn, Inflammation, Corticosteroids, Inhalation

Abstract

Bronchopulmonary dysplasia (BPD) with oxygen dependence at 36 weeks postmenstrual age (PMA), remains an important complication of premature newborns. BPD occurs due to pulmonary inflammation. Reducing pulmonary inflammation with postnatal systemic corticosteroids reduces the incidence of BPD but is associated with an increased risk of long and short-term side effects. Local administration of corticosteroids via inhalation might be an effective and safe alternative. Currently, there is no recommendation for use of inhaled corticosteroids in neonatal respiratory care. However, it is being used in neonatal intensive care units (NICU) across the world in ventilator and oxygen-dependent babies. We shared our experience with the use of inhaled budesonide on nine ventilator-dependent very low birth weight (VLBW) preterm neonates in the form of case series and review the literature. 

References

Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD neonatal research network. Pediatrics. 2010;126(3):443-56.

Bolton CE, Bush A, Hurst JR, Kotecha S, McGarvey L. Lung consequences in adults born prematurely. Thorax. 2015;70(6):574-80.

Short EJ, Kirchner HL, Asaad GR, Fulton SE, Lewis BA, Klein N, et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med. 2007;161(11):1082-7.

Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol. 1995;19(6):371-8.

Bassler D. Inhaled budesonide for the prevention of bronchopulmonary dysplasia. J Matern Fetal Neonatal Med. 2017;30(19):2372-4.

Doyle LW, Ehrenkranz RA, Halliday HL. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2014;5:001145.

Cheong JL, Anderson P, Roberts G, Duff J, Doyle LW, Victorian Infant Collaborative Study Group. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia. Arch Dis Child Fetal Neonatal Ed. 2013;98(1):32-6.

Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1996;21(5):301-9.

Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2016;138(6):20162511.

Onland W, Offringa M, Kaam AV. Late (≥7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Syst Rev. 2017;8(8):002311.

Maas C, Poets CF, Bassler D. Survey of practices regarding utilization of inhaled steroids in 223 German neonatal units. Neonatology. 2010;98(4):404-8.

Job S, Clarke P. Current UK practices in steroid treatment of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2015;100(4):371.

Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PLoS One. 2014;9(9):106838.

Ogawa R, Mori R, Sako M, Kageyama M, Tamura M, Namba F. Drug treatment for bronchopulmonary dysplasia in Japan: questionnaire survey. Pediatr Int. 2015;57(1):189-92.

Jónsson B, Eriksson M, Söder O, Broberger U, Lagercrantz H. Budesonide delivered by dosimetric jet nebulization to preterm very low birthweight infants at high risk for development of chronic lung disease. Acta Paediatr. 2000;89(12):1449-55.

LaForce WR, Brundo DS. Controlled trial of beclomethasone dipropionate by nebulisation in oxygen-dependent and ventilator-dependent infants. J Pediatr. 1993;122(2):285-8.

Pappagallo M, Abbasi S, Bhutani VK. Respiratory and systemic effects of inhaled dexamethasone on ventilator dependant preterm infants at risk for bronchopulmonary dysplasia. Indian J Pediatr. 1998;65(2):273-82.

Downloads

Published

2021-08-23

Issue

Section

Case Series